ES2542866T3 - Factor inducible por retinoides novedoso y usos del mismo - Google Patents

Factor inducible por retinoides novedoso y usos del mismo Download PDF

Info

Publication number
ES2542866T3
ES2542866T3 ES09762718.6T ES09762718T ES2542866T3 ES 2542866 T3 ES2542866 T3 ES 2542866T3 ES 09762718 T ES09762718 T ES 09762718T ES 2542866 T3 ES2542866 T3 ES 2542866T3
Authority
ES
Spain
Prior art keywords
cxxc5
protein
level
expression
inducible factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09762718.6T
Other languages
English (en)
Spanish (es)
Inventor
Johan R. Lillehaug
Frederic Pendino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vestlandets Innovasjonsselskap AS
Original Assignee
Bergen Teknologioverforing AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bergen Teknologioverforing AS filed Critical Bergen Teknologioverforing AS
Application granted granted Critical
Publication of ES2542866T3 publication Critical patent/ES2542866T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09762718.6T 2008-06-09 2009-06-09 Factor inducible por retinoides novedoso y usos del mismo Active ES2542866T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NO20082550 2008-06-09
NO20082550 2008-06-09
NO20090358A NO20090358L (no) 2008-06-09 2009-01-23 Retinoid-induserbar faktor, og anvendelse derav
NO20090358 2009-01-23
PCT/NO2009/000214 WO2009151337A2 (en) 2008-06-09 2009-06-09 Novel retinoid inducible factor and uses thereof

Publications (1)

Publication Number Publication Date
ES2542866T3 true ES2542866T3 (es) 2015-08-12

Family

ID=41328567

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09762718.6T Active ES2542866T3 (es) 2008-06-09 2009-06-09 Factor inducible por retinoides novedoso y usos del mismo

Country Status (7)

Country Link
US (1) US20120003181A1 (enExample)
EP (1) EP2321343B1 (enExample)
JP (1) JP5797554B2 (enExample)
DK (1) DK2321343T3 (enExample)
ES (1) ES2542866T3 (enExample)
NO (2) NO20090358L (enExample)
WO (1) WO2009151337A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616540T3 (es) 2010-07-21 2017-06-13 Bergen Teknologioverføring As Métodos para determinar un pronóstico de supervivencia para un paciente con leucemia
KR101721028B1 (ko) * 2014-02-12 2017-03-29 연세대학교 산학협력단 상처 치유 촉진용 조성물
WO2024074713A1 (en) * 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
CN116004829A (zh) * 2023-01-04 2023-04-25 上海良福生物科技有限公司 一种notch1的胞内活化结构域（nicd1）调节剂及其应用
CN119060944B (zh) * 2023-05-31 2025-11-11 士泽生物医药（苏州）有限公司 利用粒细胞集落刺激因子诱导心肌细胞分化成熟的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6906800A (en) * 1999-08-17 2001-03-13 Incyte Genomics, Inc. Membrane associated proteins
CA2625403A1 (en) * 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use

Also Published As

Publication number Publication date
WO2009151337A3 (en) 2010-07-08
EP2321343B1 (en) 2015-06-03
WO2009151337A2 (en) 2009-12-17
NO20090358L (no) 2009-12-10
NO20100815A1 (no) 2011-03-09
EP2321343A2 (en) 2011-05-18
DK2321343T3 (en) 2015-08-24
US20120003181A1 (en) 2012-01-05
JP2011525352A (ja) 2011-09-22
JP5797554B2 (ja) 2015-10-21

Similar Documents

Publication Publication Date Title
ES2542866T3 (es) Factor inducible por retinoides novedoso y usos del mismo
JP5490343B2 (ja) Ｊｎｋシグナル導入経路の細胞透過性ペプチドインヒビター
ES2582208T3 (es) Marcador molecular para células madre cancerosas
ES2818921T3 (es) Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo
AU2014235039B2 (en) Stabilized EZH2 peptides
ES2473274T3 (es) Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK
ES2361541T3 (es) Genes y polipéptidos relacionados con cánceres de colon humanos.
US20200171120A1 (en) Saposin-a derived peptides and uses thereof
Badri et al. Blood pressure homeostasis is maintained by a P311–TGF-β axis
Zhu et al. REGγ drives Lgr5+ stem cells to potentiate radiation induced intestinal regeneration
JP2009523156A (ja) 癌の処置のためのγ線照射と組み合わせた化合物の使用
Chen et al. Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling
DK2406279T3 (en) Compositions for prevention and treatment of neurodegenerative diseases
Yuan et al. Nuclear protein profiling of Jurkat cells during heat stress‐induced apoptosis by 2‐DE and MS/MS
Deucher et al. The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity.
Otto et al. Identification of blottin: A novel gastric trefoil factor family‐2 binding protein
EP2069791B1 (en) Cellular receptor for antiproliferative factor
EP2170364A2 (en) Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
Ito et al. Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo
CN104328130A (zh) 柔嫩艾美耳球虫入侵相关蛋白Et CHP559基因及其应用
田渕圭章 et al. Silencing heat shock transcription factor 1 using small interfering RNA enhances mild hyperthermia and hyperthermia sensitivity in human oral squamous cell carcinoma cells
US20140243268A1 (en) ERBB2 Peptides
Zhou et al. Stabilisation of PRCP by deubiquitinase‐targeting chimera (DUBTAC) to replenish autophagy for ameliorating pathological cardiac hypertrophy
Alqahtani et al. A Rat Model of Rheumatoid Arthritis: TDZD-8 is Associated with the Protection Against the Induction of the Synovium Knee Joint IL-17A/GSK3β/ROS/α-SMA Axis of Fibrosis.
Alqahtani et al. Un Modelo de Rata de Artritis Reumatoide: TDZD-8 está Asociado con la Protección Contra la Inducción del Eje de Fibrosis de la Articulación Sinovial de la Rodilla IL-17A/GSK3β/ROS/α-SMA